GlassScriptPhysician profile
Victor M Byrd
NPI 1952392797
$246,924.08
in general payments reported to CMS, 2019-2025
37 companies · $31K in 2025
The $31K reported for 2025 was more than what 94% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70K · 2020: $29K · 2021: $14K · 2022: $41K · 2023: $33K · 2024: $28K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Food and Beverage: $13K · Consulting Fee: $13K · Travel and Lodging: $2,797 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,085.00 |
| Food and Beverage | $13,431.05 |
| Consulting Fee | $12,622.50 |
| Travel and Lodging | $2,796.81 |
| Education | $196.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $80,039.63 | 2019-2025 | Rinvoq, Skyrizi |
| Lilly USA, LLC | $44,167.30 | 2019-2024 | Taltz |
| Novartis Pharmaceuticals Corporation | $42,485.50 | 2019-2025 | |
| Amgen INC. | $30,626.05 | 2019-2025 | Otezla, Otezla, Enbrel |
| Celgene Corporation | $24,539.04 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $9,069.85 | 2019-2025 | Orencia |
| Janssen Biotech, INC. | $3,634.40 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Horizon Therapeutics Plc | $3,335.50 | 2020-2023 | Krystexxa, Tepezza |
| Ucb, INC. | $2,279.81 | 2019-2025 | Cimzia, Bimzelx |
| Fresenius Kabi USA, LLC | $1,596.38 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,053.55 | 2021-2025 | Saphnelo |
| Pfizer INC. | $1,005.52 | 2019-2025 | |
| Glaxosmithkline, LLC. | $446.03 | 2021-2025 | Benlysta, Nucala |
| Ani Pharmaceuticals, INC. | $390.32 | 2023-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.31 | 2021-2025 | Cyltezo, Spevigo, Ofev |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $227.62 | 2021-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $216.52 | 2022-2025 | Acthar |
| Genzyme Corporation | $211.24 | 2023-2025 | |
| Sobi, INC | $202.68 | 2020-2025 | |
| Radius Health, INC. | $168.91 | 2020-2025 | Tymlos |
| Organon LLC | $158.43 | 2023-2025 | Hadlima, Renflexis |
| Genentech USA, INC. | $148.44 | 2019-2025 | Actemra, Gazyva |
| Pacira Therapeutics, INC. | $128.67 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $70.03 | 2024-2025 | Onpattro |
| Teva Pharmaceuticals USA, INC. | $68.49 | 2023-2024 | Simlandi, Truxima |
| Kiniksa Pharmaceuticals, LTD. | $57.50 | 2023 | Arcalyst |
| Alexion Pharmaceuticals, INC. | $52.36 | 2025 | Strensiq |
| Celltrion USA INC. | $48.36 | 2023 | Yuflyma |
| Actelion Pharmaceuticals US, INC. | $47.82 | 2023 | Uptravi, Opsumit |
| Kiniksa Pharmaceuticals International, Plc | $38.18 | 2024 | Arcalyst |
| Tersera Therapeutics LLC | $37.83 | 2025 | Quzyttir |
| Sandoz INC. | $36.63 | 2023-2024 | Hyrimoz |
| Depuy Synthes Sales INC. | $23.24 | 2025 | Orthovisc, Monovisc |
| Takeda Pharmaceuticals U.S.A., INC. | $15.10 | 2024 | |
| Mylan Institutional INC. | $13.92 | 2023 | Hulio |
| Hikma Pharmaceuticals USA | $13.11 | 2019 | |
| Sanofi-Aventis U.S. LLC | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.